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SUMMARY
Eﬀective vaccines are available for many protozoal diseases of animals, including vaccines for zoonotic pathogens and
for several species of vector-transmitted apicomplexan haemoparasites. In comparison with human diseases, vaccine
development for animals has practical advantages such as the ability to perform experiments in the natural host, the option to
manufacture some vaccines in vivo, and lower safety requirements. Although it is proper for human vaccines to be held to
higher standards, the enduring lack of vaccines for human protozoal diseases is diﬃcult to reconcile with the comparatively
immense amount of research funding. Common tactical problems of human protozoal vaccine research include reliance
upon adapted rather than natural animal disease models, and an overwhelming emphasis on novel approaches that are
usually attempted in replacement of rather than for improvement upon the types of designs used in eﬀective veterinary
vaccines. Currently, all eﬀective protozoal vaccines for animals are predicated upon the ability to grow protozoal organisms.
Because human protozoal vaccines need to be as eﬀective as animal vaccines, researchers should beneﬁt from a comparison of
existing veterinary products and leading experimental vaccine designs. With this in mind, protozoal vaccines are here
reviewed.
Key words: Protozoal diseases, attenuation, vaccination, eﬃcacy, review, animal models of human disease, malaria, one
medicine, apicomplexa.
INTRODUCTION
Eﬀective vaccines are available for many protozoal
diseases of animals (see Tables 1–4). In contrast, no
vaccine is widely available for any protozoal disease of
humans, despite great need and considerable eﬀort.
Some of the more important protozoal diseases of
humans for which vaccines could be invaluable
include falciparum malaria, vivax malaria, Chagas’
disease, African trypanosomiasis, visceral leishman-
iasis, cutaneous leishmaniasis, cryptosporidiosis, and
giardiasis.
In comparison to animal vaccine research, human
vaccine research has an extra high hurdle in needing
to test vaccine eﬃcacy within humans themselves.
Nevertheless, this problem is not insurmountable,
and numerous highly credible experiments and ﬁeld
trials have been performed on humans (Armijos et al.
2003; Roestenberg et al. 2009; Olotu et al. 2013;
Seder et al. 2013). So why is it that protozoal vaccines
are only available for animals? A number of factors
are suggested later in this review.
Indeed, several eﬀective veterinary vaccines do
have designs that should be suitable for human
vaccines. Vaccine designs that have had repetitive
veterinary successes should be considered for adap-
tation forhumanvaccines.Protozoal vaccine scientists
should familiarize themselves with the comparative
performance records of the various design categories
of experimental and commercial vaccines, and in
particular they should analyse the properties and
production methods of the best vaccines that have
been used to combat animal diseases.
The following sections of this analytical review
article describe the main classes of veterinary
protozoal vaccine designs. Illustrative details are
provided of the composition and performance of
several vaccines, most of which are in current use;
readers who prefer less detail may skip to the short
descriptions listed in Tables 1–4. Experimental
protozoal vaccines are then presented in two sections,
the ﬁrst describing experimental vaccines with good
evidence of eﬃcacy, and the second analysing several
prominent types of experimental malaria vaccines;
these are summarized in Tables 5 and 6. Factors are
then suggested to account for the general diﬀerences
in performance of each of these vaccine classes, and
suggestions are oﬀered to assist in the development
of eﬀective protozoal vaccines for both animals and
humans.
Throughout this manuscript, a vaccine is con-
sidered to have eﬀective immunity or to demonstrate
eﬃcacy if it prevents infection or reduces disease
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incidence or severity, provided that such beneﬁts
extend for a useful period of time under ﬁeld con-
ditions. No assumptions are made about vaccine
eﬃcacy based on humoral, cellular, or innate immune
response data, or experiments in vitro or within non-
target animal models.
PROS AND CONS OF VETERINARY VERSUS
HUMAN VACCINE RESEARCH
Comparative advantages for veterinary
vaccine development
Vaccine development for animal diseases has the
following advantages over vaccine development for
human diseases.
Infectious challenge experiments. Development of
vaccines for animals usually includes infectious
challenge experiments using the natural animal host
(Cornelissen and Schetters, 1996; Shkap and Pipano,
2000), enabling experiments with high predictive
value to advance rapidly. Performing similar trials in
humans has greater ethical and regulatory burdens
and can be impossible or require compromise of
experimental design. Therefore, initial eﬃcacy data
for humansmay have to be acquired in the ﬁeld under
circumstances which can be diﬃcult to control.
In vivo production of organisms. A second advantage
in the development of animal protozoal vaccines is
the option to manufacture vaccine organisms in vivo.
Poultry coccidiosis vaccines are produced by infec-
tion of birds and collection and puriﬁcation of
organisms from their feces or intestines (Williams,
2002; Sharman et al. 2010).Many babesiosis vaccines
are produced by infection of splenectomized animals
and harvesting the infected erythrocytes (Callow
et al. 1997). Although this is a clear manufacturing
advantage, any vaccine that contains animal products
is subject to marketing and regulatory disadvantages
regarding international registration and importation.
Less rigorous regulation. Licensing requirements for
human vaccines are stringent in modern industrial
nations, including a requirement to demonstrate
eﬃcacy (see Gruber, 2011 for a review of US
regulations). In comparison, animal vaccines have
often appeared to have lower regulatory hurdles, as
evidenced by commercial sales of various products
prior to clear demonstration of eﬃcacy (Choromanski
and Block, 2000;Witonsky et al. 2004). Regulation of
veterinary products in the European Union and the
USA is becoming more rigorous (as reviewed by
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Table 2. Protozoal vaccines that contain live attenuated organisms




















rapid passage in mice.
Can’t encyst. In use since
1988
(Wilkins et al. 1988;




















several times by adapting





Hall et al. 1999;

























adults. An in vitro
produced vaccine used in
Argentina appears to be
well attenuated
(Callow et al. 1997;





































Comparative advantages for human
vaccine development
Research funding. Naturally, public demand is
much greater for treatments and vaccines to combat
human diseases than for animal diseases. As a result,
vastly more funding is available for human disease
research of all types in comparison with animal
disease research. For example, the 2012 budget for
the US National Institutes of Health (NIH, 2012),
which exists to perform and support human medical
research, was $25·38 billion. In comparison, the US
Department of Agriculture funds intramural animal
health research via the Agricultural Research Service
(ARS), and extramural animal health research via
the National Institute for Food and Agriculture
(NIFA). The ARS budget in 2012 that was allocated
for ‘animal protection’, denoting animal disease
research, was $0·08 billion (USDA, 2012). The last
thorough analysis of NIFA’s extramural research
support was for a period ending in 2007 (NIFA,
2009), a year when approximately $0·05 billion was
awarded for animal disease research. Although it isn’t
possible to compare with precision, NIH (human)
and USDA (animal) health and disease research
budgets clearly diﬀer by orders of magnitude, and
similar funding trends are apparent in the size and
number of private charities and commercial indus-
tries that are devoted to human or animal health. This
general funding environment aﬀects all types of
disease research, including eﬀorts to develop proto-
zoal vaccines.
Product pricing. Manufacturers of human
vaccines beneﬁt from signiﬁcantly higher prices and
increased demand for their products as a result of
human priorities, medical insurance, government
and school policies, and international humanitarian
eﬀorts. Pricing of livestock vaccines can be meagre in
comparison; poultry coccidiosis vaccines are exam-
ples of products fromwhichmanufacturers need high
volumes to compensate for exceptionally low prices
(Williams, 2002).
TYPES OF PROTOZOAL VACCINES IN USE
Most existing protozoal vaccines are for pathogens in
the phylum Apicomplexa. Members of this phylum
are obligate intracellular parasites that actively invade
host cells and have both asexual and sexual repro-
ductive cycles.
A small number of vaccines have been produced
for non-Apicomplexan protozoa. These organisms
only have asexual reproduction. Amastigotes of
Leishmania spp. multiply within phagocytes of
the vertebrate host although they do not invade
non-phagocytic cells, and the promastigote stages
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Table 4. Protozoal vaccines that contain deﬁned antigens or antigen extracts

















in vitro axenic culture
of L. donovani
(not L. infantum)
Field trials support eﬃcacy in
reducing prevalence of infection
and disease in dogs. Injection
reactions common but not
serious. Epidemiological




2002; Nogueira et al.
2005; Palatnik-de-


















protected dogs from infectious
challenge 8m after vaccination,
and in a ﬁeld trial showed 92%
eﬃcacy over 2 years
(Lemesre et al. 2005;


















Licensed in Brazil since 2007.
Partial protection in 7 dogs
demonstrated in severe IV
challenge administered 4 weeks
after vaccination. No further
information regarding lab or
ﬁeld studies
(Fernandes et al. 2008)
Coccidiosis
of chickens











In vivo growth of






Maternal immunity is boosted
by natural exposure of hatchlings
to coccidia. Each vaccine dose
is relatively costly, but passive
immunity extends to many
eggs/chicks. Eﬃcacy supported
by challenge experiments and
production data

















disease severity in vigorous IV
heterologous challenge.
Injection site reactions reported.
No published epidemiological
investigations
(Schetters et al. 2001;











Table 5. Experimental animal and human immunizations using whole protozoal organismsa
Target Animal Pathogen Immunization procedure Adverse events Challenge protocol Results Selected citations
Avian malaria Canary Plasmodium relictum Sporozoites dissected from
mosquitoes, held in physiological
solution 12–48 h, and inoculated
1×SC
In 24 birds, 1 had severe
and 2 had weak
parasitaemias when
sporozoites held <24 h;
21 had no parasitaemia
when held between
12–48 h




All 44 control birds developed
malaria. Of 24 immunized
birds: 1 had severe, 7 had mild
and 16 had no parasitaemia
(Sergent and
Sergent, 1910)
Falciparum malaria Human Plasmodium
falciparum
Volunteers were bitten by 12–15
infected mosquitoes, 3×, while
on chloroquine
Malaria did not occur
during this period
Bite of 5 mosquitoes, 2 m
after 3rd exposure and
1m after chloroquine
Malaria occurred in 5 of 5








(a best protocol). 5×104 IV, 3×
No illness reported. Severe challenge with 500
sporozoites IV, 2 weeks
after 3rd vaccination.
Death as endpoint
All 20 control birds died but all
20 immunized birds survived
with mild to minimal
parasitaemia
(Richards, 1966)








Bite of 3 mosquitoes,
*3 weeks after 5th
vaccination
Malaria occurred in 5 of 6
control subjects but in 0 of 6
vaccinates





Bradyzoites PO, 2×, using sexually
incompetent strain
No adverse event





bradyzoites in 200 cysts,
47 days after 2nd
vaccination
All 6 unvaccinated control cats
shed oocysts, but 0 of 24








Cat trapping attempted during
7 visits to 8 farms over 3 years.
Trapped cats administered live
cryopreserved bradyzoites PO up
to 2×
Not monitored. n.a. Signiﬁcantly more cats were
found shedding T. gondii
oocysts prior to vaccinations.
Progressive, statistically
signiﬁcant reductions of
infection prevalence in pigs and








ID, 2×, killed promastigotes, mix
of 3 isolates produced in vitro.
BCG adjuvant





n.a. Within 1 year of vaccination, 2%
of vaccinates vs 8% of controls









1×, PO oocysts, killed by
lyophilization, at 0–1 day age
None reported 105 live oocysts PO
at 7 days age
In 10 controls and 9 vaccinates,
mean duration of diarrhoea was
4 vs 1·7 days, and mean
duration of oocyst shedding 5·3





1×, PO, live, in vitro high-passage
attenuated trophozoites into the
crop of 1 day old poults









trophozoites either at 15
or 29 days age
All 28 controls developed fatal
histomoniasis. Only 4 of 14
vaccinated birds challenged at
15 days survived, but all 14
vaccinated birds challenged at
29 days remained clinically
















Table 6. Representative comparisons of molecular malaria vaccine designs and their performance in artiﬁcially adapted animal models and human trialsa
Vaccine design
Correlation between animal




Weak P. berghei in mouse CSP repetitive moiety
(CS170) conjugated to BSA.
In vitro synthesis of
CSP element
5× SC Mice challenged with sporozoites 2
weeks after vaccination. Best
protocol resulted in sterile
immunity in 7 of 7 mice
(Reed et al. 1996)
P. falciparum in
humans
RTS,S fusion protein has
half of CSP& entire surface




3×IM This recombinant protein was ﬁrst
described in 1988. The best
performing vaccine of this type.
Latest ﬁeld trials achieved 1 year
eﬃcacy of 44% in children and
30% in infants. Eﬃcacy reduces
over time despite frequent natural
exposure
(Rutgers et al. 1988;
Bejon et al. 2008;
Agnandji et al. 2012;





Poor P. falciparum in
Aotus monkeys
Pf MSP-1 Recombinant ag
from transfected
E. coli
2×IM Protected 6 of 6 monkeys against
uncontrolled parasitaemia
following lethal (for naive
monkeys) IV challenge with
infected erythrocytes, 7 weeks
after vaccination
(Darko et al. 2005)
P. falciparum in
humans
Pf MSP-1 As above 3×IM Vaccine eﬃcacy<15% in ﬁeld trial.
Children followed 6m after last
vaccination




Poor P. falciparum in
Aotus monkeys





3×SC Protected 3 of 3 monkeys against
parasitaemia from IV inoculation
of P. falciparum sporozoites, 2 m
after 3rd vaccination
(Perlaza et al. 2008)
P. falciparum in
humans
Pf LSA-NRC As above 2×IM All 22 volunteers became
parasitaemic after being bitten by
5 infected mosquitoes, 2 weeks
after 2nd vaccination




Poor P. knowlesi in
rhesus monkeys
4 Pk ag & 3 cytokines
encoded in plasmids,
followed by live virus








Infectious challenge 2 weeks after
viral boost. All 4 unvaccinated
monkeys were treated for
overwhelming parasitaemia. Of 11
vaccinated monkeys, sterile
immunity occurred in 2 and
spontaneous resolution of
parasitaemia occurred in 7
(Rogers et al. 2002)
P. falciparum
in humans
Pf ME-TRAP in plasmid,
followed by live virus with






7 of 8 volunteers develop
parasitaemia after being bitten by
5 infected mosquitoes, 2 weeks
following last vaccination with
ME-TRAP. Parasitaemia was
delayed 1 day. CS vaccine regimen
had no protective eﬀect
(Dunachie et al. 2006)









Giardia lamblia and Tritrichomonas foetus are strictly
extracellular parasites.
Tables 1–4 provide examples of the types of
protozoal vaccines that are in current use or have
been in recent distribution.
Human immunizations
Leishmanization. OldWorld and NewWorld forms
of cutaneous leishmaniasis are similar conditions
caused by diﬀerent species of Leishmania, which are
transmitted by the bite of various phlebotomine
sandﬂies. Infected bites may develop into chronic,
ulcerated wounds (Ameen, 2010). Although most
lesions ultimately resolve, disﬁguring scars may
result which can be particularly distressing when
they occur on the face. Leishmanization is a
controlled-exposure type of immunizing procedure
that has been used to protect against cutaneous
leishmaniasis (Table 1). Similar procedures were
developed and used by several governments in the
Middle East and central Asia, and related natural
exposure practices (to sandﬂies) had been in prior
use. In Iran, live virulent trophozoites of Leishmania
major were produced by intraperitoneal mouse
passage followed by limited axenic passage in broth
(Nadim et al. 1983). The fresh live inoculum was
administered intradermally or by scariﬁcation at a
site in an arm or shoulder. If the procedure was a
‘take’, then a cutaneous lesion would develop at the
inoculation site. This wound could endure months
and in some cases longer than a year before healing
with a scar. Immunized individuals were protected
from disﬁguring scars on the face that may result
from natural exposure to L. major-infected sandﬂy
vectors.
Quality assurance of these biological products was
diﬃcult. Adverse events were reported, most notably
including persistent sores. Despite these problems,
leishmanization was credited with greater than 80%
reduction of disease prevalence (Nadim et al. 1997).
A review by Dunning (2009) reported that leishma-
nization was recently employed in Uzbekistan.
Malaria fever therapy. To the author’s knowledge,
no other human protozoal immunizations have
achieved widespread use, other than the possible
historical inclusion of virulent malaria inoculations
for fever therapy of neurosyphilis (‘general paralysis
of the insane’) practiced in the early and mid-20th
century. The intention was not to immunize against
malaria, but rather to induce a high fever that would
kill or control Treponema pallidum and thereby halt
or reduce neurological impairment (as reviewed by
Kragh, 2010) . Case reports have been compiled and
examined for the eﬀect upon the course of malaria
itself when induced in patients more than one time,
but highly varied treatment regimens and the
understandable lack of controls make conclusions
diﬃcult (Collins and Jeﬀery, 1999).
Immunization using controlled-exposure and
infection-and-treatment protocols (see Table 1)
A logical improvement upon immunization
with virulent organisms without treatment, where
the infection is allowed to run its full course
(controlled-exposure), is to infect patients with
virulent organisms and then administer a pro-
phylactic antimicrobial (infection-and-treatment).
This practice is still widely used for East coast fever
of cattle, and until recently was a common technique
for control of poultry coccidiosis. An infection-
and-treatment protocol was also recently used for
experimental immunization against human malaria
(Roestenberg et al., 2009; Table 5).
East coast fever of cattle. This is an economically
important disease in eastern, central and southern
regions of Africa. The causative organism isTheileria
parva. Regionally varied species, subspecies, or
variants of T. parva exist for which cross-protection
may be poor (reviewed by Uilenberg, 1999). The
parasite is transmitted by Rhipicephalus ticks and
causes high mortality in Bos taurus cattle, less
mortality in Bos indicus cattle, while native species
of buﬀalo appear to be well-adapted natural reser-
voirs. Organisms transmitted by ticks invade, repli-
cate within, and transform bovine lymphocytes, prior
to invading erythrocytes from whence they are
ingested by ticks; sexual recombination occurs in
the tick prior to forming sporozoites within salivary
glands.
These organisms are diﬃcult to cultivate in vitro
and reliable attenuation has not been achieved.
Virulent seed stock organisms are used to infect
cattle in the vaccine production process, which are
then used to infect ticks. Organisms are harvested
from tick salivary glands and are semiquantiﬁed, may
be cryopreserved, and are used to immunize cattle in
the ﬁeld. Cattle are protected from disease by
simultaneous injection of a long-acting formulation
of oxytetracycline (Radley et al. 1975). Eﬃcacy of this
infection-and-treatment protocol is high and protec-
tion endures at least 3 years, but sterile immunity is
not achieved. Immunized animals develop a carrier
state with potential to transmit virulent organisms to
ticks.
A multivalent vaccine (the Mugaga cocktail)
(Patel et al. 2011), originally developed by the East
African Veterinary Research Organization (now the
Kenya Agriculture Research Institute), is licensed
and being produced by a commercial enterprise
for distribution in Kenya, Tanzania and Malawi
(GALVmed, 2010). Diﬀerent vaccine seed stocks are
used in other regions. It is possible to immunize cattle
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in Zimbabwe using low-titration doses of the Boleni
stock of T. parva without concurrent administration
of antibiotics, attributed to its lower virulence (Latif
and Hove, 2011).
The life cycle of the parasites of bovine theilerioses
shares certain generalized features with that of
malaria parasites, including sexual reproduction
within a haematophagous arthropod vector, initial
invasion within nucleated cells of the vertebrate host,
and subsequent invasion of erythrocytes (Marquardt
et al. 2000). Furthermore, infection-and-treatment
protocols using the corresponding sporozoites induce
protection against each of these diseases (Radley et al.
1975; Roestenberg et al. 2009).
Poultry coccidiosis. Eimeria spp. are coccidia of
major economic importance to poultry industries
around the world. These fecal-oral pathogens have a
direct life cycle. Oocysts are excreted in feces and
sporulate upon exposure to air. Ingested oocysts
excyst in the gastrointestinal tract to release spor-
ozoites, which invade host enterocytes. Each species
undergoes a set number of asexual replication cycles
within the intestinal tract, ultimately producing
gametocytes that combine sexually and become
oocysts (McDougald, 1998).
Live oocysts of various Eimeria spp. are puriﬁed
from the feces of birds used for vaccine production.
On farms, oral inoculation of hatchlings with
mixed species of coccidial oocysts is used to induce
protective immunity. Today, most if not all live
coccidiosis vaccines are recommended to be applied
without use of anticoccidial drugs, and thus they rely
solely upon the birds’ ability to mount an eﬀective
immune response before serious superinfections
can result from re-exposure to organisms in litter.
Nevertheless, organism strains used in live vaccines
are selected for their continuing sensitivity to anti-
coccidial drugs. Although now falling out of favour,
a common practice was to vaccinate birds and then
add low levels of coccidiostatic drugs to feed or water
(i.e. infection-and-treatment) (reviewed byWilliams,
2002).
Vaccinal protection from disease results from a
combination of vaccine-induced immunity, immu-
nological boosting from environmental re-exposure
to vaccinal and wild type organisms, and displace-
ment or dilution of coccidiostat-resistant strains in
litter that otherwise may be prevalent (presumably
this is in case anticoccidial treatment should become
necessary). Because meat-producing birds have such
short lifespans, induction of short-term immunity
may be all that is required of a vaccine for broilers.
Live attenuated vaccines (see Table 2)
A superior concept to controlled-exposure or infec-
tion-and-treatment strategies, when possible, is to
develop vaccines that contain live but attenuated
organisms that are unlikely to cause disease. The best
performing protozoal vaccines have this design.
Vaccinal organisms are sometimes manufactured
in vivo, including many babesiosis vaccines and all
attenuated coccidiosis vaccines; clearly, those pro-
duction strategies are unsuitable for adaptation to
purely human conditions. However, several attenu-
ated vaccines are produced in vitro, have been
attenuated using repeatable methods, and show little
evidence of vaccine-associated adverse events; similar
designs merit strong consideration for development
of protozoal vaccines for human diseases.
Bovine tropical theileriosis. The causative organism,
Theileria annulata, is a blood-borne apicomplexan
parasite that is transmitted by an arthropod vector
(Hyalomma ticks). Disease commonly occurs in
highly susceptible B. taurus cattle in countries
bordering the Mediterranean Sea and extending
southward into Sudan and eastward into China and
India.
Organisms are transmitted to cattle by ticks to
invade, replicate within, and cause clonal expansion
of macrophages and lymphocytes, prior to invading
erythrocytes from whence they are ingested by other
ticks. This species of Theileria is adaptable to in vitro
culture within bovine macrophages or lymphoid
cells. Many strains have become attenuated simply
by prolonged passage in cell culture (Boulter and
Hall, 1999; Gubbels et al. 2000). Attenuation has
been associated with loss of expression of parasite-
induced matrix metalloproteinases, which hinders
systemic dissemination of organisms (Hall et al.
1999). Although vaccine strains may cause cryptic
infections, latent organisms are incapable of trans-
mission to ticks (Gubbels et al. 2000).
High rates of vaccine eﬃcacy (>90%) and safety
(100%) have been claimed (Zhang, 1997; Boulter and
Hall, 1999) with little if any evidence of reversion to
virulence. Immunity is cross-protective among
strains (Boulter and Hall, 1999). Vaccinal protection
endures at least 19 months in the ﬁeld (Yin et al.
2008), although there is room to question whether the
duration of vaccine eﬃcacy might depend upon
repeated exposure to infected ticks.
Similar vaccines for Theileria lestoquardi
(Theileria hirci) are used in Iran, Iraq and Bulgaria
to protect sheep from malignant ovine theileriosis
(Hooshmand-Rad, 1985; Lawrence, 1997; Ali et al.
2008).
Toxoplasmosis abortion. An attenuated vaccine pre-
vents Toxoplasma gondii-induced abortion in sheep
(Buxton, 1993). This vaccine has been in continuous
production since 1988 and is currently marketed in
NewZealand and parts of Europe. It contains the S48
strain of T. gondii, which lost the ability to transform
into the bradyzoite stage during years of twice-weekly
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intraperitoneal passage of tachyzoites in mice – such
rapid passage did not allow time for stage conversion
to form bradyzoites, and the strain lost this ability
(Buxton and Innes, 1995). For the commercial
production of the vaccine, the S48 strain is now
maintained in tissue culture.
Ewes are vaccinated once, at least 3 weeks before
breeding. Vaccination causes a transient fever and
then the infection is cleared, unlike natural infections
in which bradyzoites form latent intracellular cysts
within brain and muscle. The inability to encyst
makes the vaccine acceptable to use in a food-
producing animal; otherwise, vaccine organisms in
raw tissues could transmit infections to people and
cats.
Vaccinal protection from toxoplasmosis abortion is
strong against heterologous challenge with ingested
oocysts (Wilkins et al. 1988), which has been tested
out to 18 months post vaccination (Buxton et al.
1993). The manufacturer recommends revaccination
in 2 years.
There are product warnings against vaccination of
ewes during pregnancy, and because toxoplasmosis is
a zoonotic disease there are further warnings about
accidental human inoculation, particularly of preg-
nant women or immunosuppressed individuals. The
author has been unable to ﬁnd information to suggest
that an adverse event may have occurred in people or
that abortions in ewes may have been caused by
inadvertent vaccination during pregnancy; this ab-
sence of published adverse events, after 25 years of
commercial use, suggests (but does not prove) that
despite the hypothetical concerns, any risks asso-
ciated with the vaccine may in fact be minimal.
Bovine babesiosis. Babesia spp. are apicomplexan
parasites of erythrocytes that are transmitted by tick
vectors. Infection causes a febrile haemolytic disease.
Morbidity and mortality can be particularly severe in
B. taurus cattle.
Many bovine babesiosis vaccines are currently
produced by governmental organizations around the
world. Most are produced in vivo within splenecto-
mized calves and contain Babesia bovis, Babesia
bigemina, or both species. Many babesiosis vaccines
may induce clinical disease; for example, a Cuban
vaccine (Alonso et al. 1994) was reported to have a 2%
rate of post-vaccination incidents. Vaccine risks are
greater in adults (mirroring natural disease risks),
so vaccinations are typically restricted to juveniles.
Despite these limitations, babesiosis vaccines have
been widely used in tropical and subtropical regions
and have greatly reduced the incidence of disease
losses (Callow et al. 1997).
A babesiosis vaccine currently in use in Argentina
merits special attention because it is produced in vitro
within bovine erythrocytes (Mangold et al. 1996),
although it is not the only babesiosis vaccine to be
cultured in this way (reviewed by Shkap and Pipano,
2000). Millions of doses of the combined B. bovis –
B. bigemina vaccine have been used in Argentina,
with failure of protection documented in 0·09% of
vaccinated cattle (Echaide, 2008). The B. bovis
fraction is known to have lost the ability to be
transmitted to tick vectors.
In Europe, bovine babesiosis is caused by Babesia
divergens, and vaccines have been produced for that
pathogen (reviewed by Bock et al. 2008; Zintl et al.
2003). Many methods of attenuation and production
were reported including in vivo within splenecto-
mized calves and also within Mongolian gerbils
(Meriones unguiculatas), or in vitro within erythro-
cytes. The use of gerbils for vaccine production was
thought to have biosecurity and safety advantages
over use of calves, however no more than 200 vaccine
doses could be generated from a single gerbil. The
apparent paucity of B. divergens vaccines available at
present may have been inﬂuenced in part by the
bovine spongiform encephalopathy epidemic in
Europe and heightened concerns about disease
transmission risks of bovine biological products.
An attenuated vaccine for Babesia ovis has been
used to protect sheep in Bulgaria (Lawrence, 1997).
Precocious coccidiosis vaccines. An alternative to
infection-and-treatment coccidiosis immunization
protocols is the use of attenuated vaccines. The
elegant ‘precocious’ method of attenuation was ﬁrst
described for Eimeria tenella (Jeﬀers, 1975), and the
same method has been eﬀectively applied to multiple
species of poultry coccidia. Precocious strains of
Eimeria spp. are selected by collecting the earliest
forming oocysts from each infection, using those
oocysts to infect the next subject, collecting the
earliest oocysts again, and so on for multiple
generations. Prepatent periods become shortened;
this eﬀect can be the result of the loss of one or more
asexual cycles in the intestinal tract prior to game-
togony (McDougald and Jeﬀers, 1976), or by a
shortening of the time that each schizont takes to
develop, and/or by a reduction in the size of schizonts
and number of progeny within them (McDonald and
Shirley, 2009).
Reduced asexual reproduction of precocious
strains in the intestinal tract leads to less mucosal
damage, fewer oocysts produced, and a correspond-
ing reduction in the number of oocysts that accumu-
late in the environment (McDonald and Shirley,
2009). A manufacturing drawback is that because
fewer precocious oocysts are produced in comparison
with wild-type infections, a greater number of birds
must be used for in vivo production of vaccinal
oocysts and this increases production costs.
Precocious attenuation is a repeatable achievement
and many stable strains have been developed. The
prototype Wis-F strain of E. tenella could not be
induced to revert to a longer prepatent period or
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virulence even when it was subjected to a relaxed
selection protocol for 25 generations (Jeﬀers, 1975).
The precocious selection concept has recently been
adapted to create Eimeria spp. vaccine strains for
rabbits (Pakandl, 2005; Akpo et al. 2012), although it
is unclear whether any have progressed to commercial
use or regional distribution.
Vaccines containing whole killed protozoa (see Table 3)
Only four examples were found of commercially
marketed protozoal vaccines containing whole
killed organisms. All of these vaccines incorporate
adjuvants and require two initial immunizations.
Although these products are safe, they induce at best
only partial protection for a brief period of time.
However, even brief protection may have useful
niche applications, such as vaccination prior to the
breeding season to reduce a sexually transmitted
disease of cattle (trichomoniasis). Two of these
products have been withdrawn from the market.
Vaccines containing subunit antigens (see Table 4)
Only a few examples were found of commercially
marketed protozoal vaccines based on deﬁned or
extracted antigens. All of the products in this class
can be referred to as subunit vaccines; however, most
of them are not recombinant antigen vaccines,
because the vaccinal antigens are not derived from
artiﬁcial synthesis or from transfection of other
organisms such as bacteria, yeast, insect cells or
viral vectors. All subunit protozoal vaccines incor-
porate adjuvants and require two or three initial
immunizations.
Evidence of ﬁeld eﬃcacy has been published
for two subunit protozoal vaccines (Leishmune and
Coxabic). Unfortunately, the single example of a true
recombinant antigen vaccine (Leish-Tec) has no
documentation of ﬁeld eﬃcacy (from PubMed and
Google searches or from the manufacturer’s website).
Canine visceral leishmaniasis. Dogs and other
canids are important reservoir hosts of Leishmania
infantum, one of the pathogens of visceral leishman-
iasis (canine and human). The pathogen is trans-
mitted by sandﬂies when obtaining blood meals. In
Brazil, a commercial vaccine for dogs (Leishmune)
contains Fucose-Mannose-Ligand glycoprotein anti-
gen derived from axenic culture of L. donovani (not
L. infantum), administered with saponin adjuvant.
This antigen complex plays a role in the entry of
parasites into host phagocytes, a prerequisite for
parasite replication and traﬃcking.
In ﬁeld trials, vaccination with Leishmune reduced
the incidence of disease in dogs over several years
(Borja-Cabrera et al. 2002; Nogueira et al. 2005).
Importantly, experimental evidence indicates that
the vaccine helps to block transmission ofL. infantum
from dogs to sandﬂy vectors (Saraiva et al. 2006).
These properties are consistent with epidemiological
evidence associating vaccination of dogs with stat-
istically signiﬁcant reductions of human visceral
leishmaniasis (Palatnik-de-Sousa et al. 2009).
In addition to vaccination of dogs, public health
programmes in Brazil include identiﬁcation and
removal of Leishmania-infected dogs. This compli-
cates epidemiological analysis, so further, public-
sponsored investigations are merited to more clearly
distinguish between the degree of human protection
that is attributable to vaccination of dogs and to
culling of infected dogs, respectively.
A similar Leishmania vaccine for dogs (CaniLeish)
has been provisionally licensed in parts of Europe
(EMA, 2011). The vaccine contains Excreted
Secreted Proteins (ESP) ofL. infantum. Pre-licensing
experiments, using ESP in muramyl dipeptide as
adjuvant, demonstrated protection from infectious
challenge for at least 8 months (Lemesre et al. 2005),
and a double-blind ﬁeld trial of approximately 400
dogs showed 92% eﬃcacy in preventing infections
over a 2-year period (Lemesre et al. 2007). The
provisionally licensed formulation of CaniLeish
contains saponin adjuvant instead of muramyl
dipeptide.
A third vaccine for canine leishmaniasis, licensed
in Brazil since 2007 (Leish-Tec), is perhaps the
only marketed recombinant antigen vaccine for any
protozoal disease. It contains a Leishmania amasti-
gote antigen (A2) puriﬁed from transfected
Escherichia coli. A small trial showed partial short-
term protection of vaccinated dogs from a severe
infectious challenge (Fernandes et al. 2008). There
appear to be no further published investigations of
eﬃcacy.
Coccidiosis of chickens. A subunit vaccine containing
two native antigens extracted from Eimeria maxima
macrogametocytes is marketed for vaccination of
hens to provide passive immunization of chicks
(Coxabic) (reviewed by Sharman et al. 2010).
Organisms used in vaccine production are produced
in vivo in chickens and are extracted from the
intestinal tract. Maternal antibody is passed via the
egg to hatchlings.
Passive immunity engendered by Coxabic is
suﬃcient to enable oﬀspring to perform well and to
transition towards active immunity against mixed
Eimeria spp. as a result of ubiquitous natural
exposure. Vaccine eﬃcacy has also been inferred
from production data of large-scale ﬁeld trials in
which growth andmortality were similar between the
oﬀspring of vaccinated hens and the oﬀspring of
unvaccinated hens in which coccidiosis had been
managed using traditional industry practices (i.e.
prophylactic coccidiostatic drugs in feed, and/or use
of live vaccines) (Wallach et al. 2008). Because of its
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manner of production and application, Coxabic is
more expensive per dose than are other types of
coccidiosis vaccines, however each vaccinated hen
passes immunity to numerous oﬀspring.
Canine babesiosis. A vaccine for canine babesiosis,
containing soluble protein antigens derived from
in vitro cultures of Babesia canis and Babesia rossi,
was demonstrated to ameliorate the severity of
infectious challenge with heterologous B. canis for
up to 6 months after vaccination (Schetters et al.
2001, 2006). The infectious challenge in these
experiments was severe, having been induced by
intravenous inoculation of infected erythrocytes
rather than by the bite of infected ticks; infectious
challenge experiments that are overly harsh have the
potential to mask the protective eﬀect of a vaccine. In
these experiments, haematocrit values dropped 54%
in vaccinated dogs compared with a 65% drop in
unvaccinated controls, and clinical scores also showed
modest but statistically signiﬁcant improvements
(Schetters et al. 2006).
The vaccine was marketed in parts of Europe, but
unfortunately there was no published epidemiologi-
cal study and the product is no longer in production.
Therefore, it is unclear whether the vaccine may have
prevented or reduced transmission from ticks, or if
the eﬀects were limited to a reduction in the severity
of disease as in the challenge experiments.
Comparisons across vaccine classes
Propagation of organisms. Perhaps the single most
obvious conclusion is that the production of all
eﬀective protozoal vaccines is dependent upon
growth of protozoal organisms, either in vitro or
in vivo; this includes production of organisms within
arthropod vectors. Eﬀective vaccines don’t always
contain whole organisms, but even native subunit
vaccines require culture of organisms for extraction of
antigens. The author has found only one commer-
cially available recombinant antigen vaccine, but no
evidence has been published to support the eﬃcacy
of that vaccine in the ﬁeld. There are no licensed
protozoal vaccines based on DNA or viral vectors.
This conclusion has a profound implication: for
any protozoal disease to be controlled by a vaccine,
methods must be developed to cultivate the patho-
gen. Although breaking this paradigm is a legitimate
goal of protozoal vaccine science, vaccine designs
with this goal carry a high risk of failure.
The value of living organisms. A single inoculation of
living organisms, whether virulent or attenuated,
tends to create strong, long-lasting protection against
most protozoal diseases. The advantage of great
eﬃcacy is tempered by legitimate safety concerns,
even though many attenuated vaccines have excellent
safety records. A major rationale for research of novel
protozoal vaccine designs for human diseases has
been that live vaccines carry unacceptable risks;
however, while many novel vaccines have been safe
they have not been eﬀective. Moving forward, new
emphasis should be placed upon the development of
novel methods to improve the safety of live vaccines,
which can reasonably be expected to be eﬀective.
Uses for short-term protection. Killed and subunit
vaccines require adjuvants, booster inoculations, and
annual or semiannual revaccination. The relatively
short duration of protection is a disadvantage.
However, residents of highly endemic regions may
only need vaccinal immunity in the short term, and
then naturally acquired immunity could take over as a
result of frequent natural exposure. An example of
this is vaccination of hens to provide passive
protection of chicks from coccidiosis (Sharman
et al. 2010).
Mucosal vaccines. In relation to mucosal pathogens,
the endurance of eﬀective immunity that may be
attributed solely to live vaccination is unclear and is
worthy of further research. For example, the true
duration of eﬀective immunity resulting solely from
application of a poultry coccidiosis vaccine is
obscured by the daily natural exposure of production
birds to coccidia in litter (Williams et al. 2000).
Although this distinctionmay be unimportant for the
control of coccidiosis in poultry, the duration of
protection of mucosal vaccines in the absence of
frequent endemic exposure is an important consider-
ation for development of future veterinary or human
vaccines against diseases such as giardiasis, crypto-
sporidiosis, amoebiasis, microsporidiosis and tricho-
moniasis.
Parenteral vaccination with killed mucosal patho-
gens appears to provide modest, short-lived protec-
tion at most, and has been inadequately investigated
(Lehmann and Lehmann, 2004; Baltzell et al. 2013).
EXPERIMENTAL PROTOZOAL VACCINES
Experimental vaccines containing organisms
Table 5 gives details of several noteworthy vacci-
nation experiments that, although often highly
eﬀective, have not (or have not yet) resulted in a
marketed vaccine. All of these experiments were
based on live, attenuated, or whole-killed protozoal
organisms. The results of these studies carry great
predictive value because each was performed using a
natural host–parasite relationship.
Two human malaria trials show protective eﬃcacy
for infection-and-treatment (Roestenberg et al. 2009)
and whole-organism protocols (Seder et al. 2013);
these experimental immunization protocols have
counterparts among veterinary vaccines, and closely
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analogous experiments using avian malaria essen-
tially predicted these results as much as a century
earlier (Sergent and Sergent, 1910; Richards, 1966).
Although an intravenously administered irradiated
vaccine, recently examined by Seder et al. (2013), is
described as being metabolically active, the exper-
imental results compare closely with killed vaccines
investigated in chickens (Richards, 1966). These
investigations need to be progressed further, to
include heterologous infectious challenges at mean-
ingfully long intervals after immunization.
An attenuated vaccine to prevent cats from
disseminating T. gondii oocysts was a remarkable
scientiﬁc success but was not commercially viable.
The vaccine was designed to reduce transmission
from cats to other animals and humans. The T-263
strain of T. gondii was developed by chemical
mutagenesis and selection for the inability to undergo
sexual recombination (Frenkel et al. 1991). The
orally administered vaccine demonstrated high
eﬃcacy in infectious challenge experiments of cats
(Frenkel et al. 1991; Freyre et al. 1993). Additionally,
in an ambitious 3-year ﬁeld trial, cats were trapped
and vaccinated on swine farms. The number of cats
observed to be shedding oocysts and the T. gondii
seroprevalence of pigs and rodents on farms de-
creased signiﬁcantly (Mateus-Pinilla et al. 1999),
consistent with decreased oocyst contamination of
farms. Although eﬀective, this vaccine would have
been expensive to manufacture and distribute, and
diﬃcult to market.
Field evidence was obtained for eﬃcacy of a
vaccine to prevent human cutaneous leishmaniasis
in Ecuador, which contained three local isolates of
Leishmania spp. promastigotes that were phenol-
killed and administered with BCG adjuvant.
Vaccinated and control subjects were monitored for
a year, and cutaneous leishmaniasis occurred in 2%
and 8%, respectively (Armijos et al. 1998). The
vaccine required a booster and annual revaccination
(Armijos et al. 2003). Injection site swelling and mild
fever were frequently observed especially following
the second application; this could have been caused
by reaction to Leishmania spp. antigens or to the
BCG adjuvant. The vaccine does not appear to have
been brought forward for commercial or govern-
mental use. Another killed vaccine for human
cutaneous leishmaniasis was recently trialled in
Brazil and positive results were reported (Mayrink
et al. 2013).
An attenuated vaccine for histomoniasis of turkeys
and chickens has been developed by researchers in
Austria. The vaccinal strain became attenuated when
organisms were passaged every 2–3 days in axenic
broth culture for 295 times. The vaccine is eﬀective
when administered into the crop or into the cloaca,
and provides strong protection in challenge experi-
ments, at least against low passage virulent organisms
of the parent strain (Liebhart et al. 2010, 2013).
Histomoniasis is re-emerging as a cause of poultry
losses, in part because the prophylactic use of
eﬀective antimicrobials has been restricted or
banned. Practical issues to overcome in order to
commercialize this type of product will probably
include the economics of transportation and admin-
istration of cryopreserved vaccines, which must be
inexpensive to be used in poultry.
Experimental molecular malaria vaccines
Table 6 compares results of animal models and
human trials for several prominent types of exper-
imental malaria vaccines. Malaria has been the
dominant category of protozoal vaccine research in
recent history. All of the vaccines in Table 6 were
based on novel molecular designs.
In each comparison in Table 6, the positive results
obtained in animal models exceeded the results
obtained in humans. The following factors help
explain the poor predictive value of those experi-
ments: (1) Reliance upon artiﬁcially adapted host–
parasite models of malaria; (2) Investigation of
unreasonably short intervals between vaccination
and infectious challenge experiments; (3) Use of
homologous organisms in infectious challenge ex-
periments; (4) Vaccine designs that disregard the
history of veterinary protozoal vaccines. These four
factors are discussed in greater detail in the following
sections.
The importance of animal model selection
All of the animal malaria models in Table 6 are
artiﬁcial combinations of host and parasite. Natural
malarias have a period of acute illness, during which
mortality may occur in a minority of individuals,
typically followed by recovery with prolonged
splenomegaly, frequent development of latent
infections, and the possibility of disease relapse
(Garnham, 1966; Miller et al. 1994). Metaphorically,
there is a standoﬀ between host and parasite rather
than absolute victory for either one. In contrast,
artiﬁcially adaptedmalaria models tend to behave in a
‘winner-takes-all’ manner that does not resemble
naturally evolved malaria relationships.
Laboratory rodent-adapted Plasmodium spp. are
natural parasites ofThamnomys andGrammomys spp.
of thicket rats (Vincke and Lips, 1948; Cox, 1988),
native to montane forests of central Africa. The
ancestral lineage of these rodents diverged from that
of the house mouse over 10 million years ago
(Lecompte et al. 2008). The natural hosts are well
adapted and do not suﬀer high mortality (Garnham,
1980). In contrast, experimentalmalaria in laboratory
mice has high mortality, with many mouse–parasite
combinations being completely lethal. Rescue of
infected mice tends to cause sterile recovery
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(i.e. without chronic or latent infections) (Ishih et al.
2013). This is a winner-takes-all scenario.
Natural hosts ofPlasmodium knowlesi include long-
tailed macaques (Macaca fascicularis) and pig-tailed
macaques (Macaca nemestrina), in which the results
of infection are variable and have low mortality
(Butcher et al. 2010). Rhesus monkeys (Macaca
mulatta) are not natural hosts of P. knowlesi, and
infection in them induces fulminating parasitaemia
usually resulting in death (Collins, 1988), similar to
Plasmodium berghei infection of mice. This is another
winner-takes-all scenario.
Infection of owl monkeys (Aotus spp.) with the
human pathogen Plasmodium falciparum creates
another winner-takes-all scenario (Sadun et al. 1969).
In artiﬁcial winner-takes-all relationships, rela-
tively minor treatments may cause a radical shift
between the only twomajor outcomes, death or sterile
recovery. Researchers may mistakenly believe that
lethal models of malaria are severe tests for any
vaccine, and that survival after vaccination is therefore
evidence of great eﬃcacy. In practice, a vaccine that
reduces infectionormoderatesdisease in anynaturally
evolved host–parasite relationship is more predictive
of whatmay be expected in other animals with similar
parasites, presumably including humans. A vaccine
that ameliorates the course of naturally evolved
malarias inThamnomys rodents, pig-tailed macaques,
canaries, or chickens, should be expected to have
greater predictive value for human malaria than do
vaccines that blockmortality inmice, owlmonkeys, or
in other artiﬁcially adapted animal models.
Short testing intervals
Data for the protective eﬃcacy of most vaccines
should be assessed over a range of intervals that
extend into a useful duration. Short-lived immunity
may be adequate for poultry coccidiosis or seasonal
breeding of cattle; however, vaccines for systemic
illnesses such as malaria should be tested at least to
6 months, and preferably to a year or more.
Homologous vs heterologous infectious challenge
To be eﬀective in the ﬁeld, vaccines need to protect
against a variety of organism isolates. When possible,
vaccines should be tested by challenge with hetero-
logous organisms, rather than with the same strain
from which the vaccine was manufactured. Research
eﬀorts should include acquisition of varied isolates
for any pathogen under investigation. Ultimately,
eﬃcacymust be assessed in ﬁeld trials within endemic
regions.
Vaccine designs that are useful in animals
There is a reason why veterinary medicine hasn’t
created a bevy of recombinant antigen vaccines for
the prevention of protozoal diseases of animals – they
haven’t been suﬃciently eﬀective.
This is not to imply that such vaccine designs could
never work, or that transformational new knowledge
will never open a ﬂoodgate of eﬀective vaccines based
on novel technological advancements. Potentially
transformative but technologically diﬃcult and un-
proven vaccine designs should be investigated
ﬁrst in naturally occurring diseases of animals, not
in artiﬁcial models. Translation of a novel design
principle to human vaccines should be attempted
after it has been shown to be eﬀective against a natural
animal–parasite relationship. If science cannot create
an eﬀective recombinant antigen or plasmid vaccine
to prevent infection of (for example) rats with
T. gondii, deer mice with Babesia microti, or sparrows
with Plasmodium relictum, then it seems rather naive
to expect such designs to be eﬀective against human
protozoal diseases.
Funding for veterinary medical research is paltry
in comparison to human disease research. Human
medical research agencies should fund research of
protozoal diseases of animals in order to develop
improved vaccine methods and investigate new
paradigms. At the same time, protozoal vaccines for
people should be developed by adapting currently
eﬀective techniques from veterinary medicine.
ONE MEDICINE
The concept of ‘One Medicine’ includes the beneﬁ-
cial ﬂow of knowledge and techniques from human
medicine to veterinary medicine, and from veterinary
medicine to human medicine. However, because of
the dominance of human medical research funding,
the ﬂow of information moves predominantly from
human medicine to veterinary medicine. Human
medicine is missing signiﬁcant beneﬁts that could be
had by paying greater attention to veterinary knowl-
edge and by supporting opportunities to investigate
naturally occurring diseases of animals. This missed
opportunity is vividly illustrated by the discordance
between development of veterinary protozoal vac-
cines, of which there are many, and human protozoal
vaccines, of which there are none.
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